Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Biosafety Services LLC

Neither a doctor nor a teaching hospital

Research payments

$100,205

20 payments

Through program year 2025, Clinical Biosafety Services LLC is reported as receiving $100,205 in research payments, across 20 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $28,500 10
2024 Research $40,625 5
2021 Research $12,720 2
2020 Research $12,360 2
2019 Research $6,000 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $31,425 2 payments
  2. Kite Pharma, Inc. $22,700 5 payments
  3. Genentech, Inc. $19,080 3 payments
  4. Regeneron Pharmaceuticals, Inc. $14,500 2 payments
  5. Ferring Pharmaceuticals AS $11,000 7 payments
  6. Moderna TX, Inc. $1,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1b 2 Study of GC012F a Chimeric Antigen Receptor Tcell CAR T Therapy Targeting CD19 and B-cell Maturation Antigen BCMA in Subjects With Relapsed Refractory Multiple Myeloma $22,675 1 payment
  2. PH II Personalized Cancer Vaccine in Nsclc $19,080 3 payments
  3. Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis $14,500 2 payments
  4. A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma $8,750 1 payment
  5. A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies $7,860 1 payment
  6. A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer $6,500 4 payments
  7. A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA 3) $6,000 1 payment
  8. A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) $6,000 1 payment
  9. A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) $4,500 3 payments
  10. Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record